Results 101 to 110 of about 3,628 (221)

The G Protein-Coupled Receptor GPR17: Overview and Update

, 2016
The GPR17 receptor is a G protein-coupled receptor (GPCR) that seems to respond to two unrelated families of endogenous ligands: nucleotide sugars (UDP, UDP-galactose, and UDP-glucose) and cysteinyl leukotrienes (LTD4 , LTC4 , and LTE4 ), with ...
Ajiroghene Thomas, Andrea Spinaci, Bauer, Benned-Jensen, Benowitz, Biname, Boda, Buccioni, Bäck, Calleri, Carlén, Catia Lambertucci, Ceruti, Ceruti, Chen, Ciana, Claudia Santinelli, Coppi, Coppi, Cosentino, Daniele, Daniele, Diego Dal Ben, Dougherty, Eberini, Erb, Franke, Fratangeli, Fredriksson, Fumagalli, Fumagalli, Fumagalli, Fumagalli, Gabriella Marucci, Gregersen, Hennen, Howard, Huber, Jacobson, Jiang, Köse, Lecca, Li, Maekawa, Maekawa, Maisel, Mamedova, Mao, Mao, Marschallinger, McQueen, Meletis, Michela Buccioni, Mori, Norregaard, Parravicini, Paruchuri, Pugliese, Qi, Raport, Ren, Rosaria Volpini, Simon, Temporini, Tyler, Viganò, Yu, Zhang, Zhang, Zhang, Zhao   +70 more
core   +1 more source

Prehospital ticagrelor in ST-segment elevation myocardial infarction [PDF]

, 2014
Background:The direct-acting platelet P2Y receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI).
Baradat, Caroline, Bolognese, Leonardo, Cantor, Warren J., Cequier Fillat, Àngel R., Chettibi, Mohamed, Collet, Jean-Philippe, Ecollan, Patrick, Goodman, Shaun G., Hamm, C. W. (Christian W.), Hammett, Christopher J., Heutz, Wim M.J.M., Huber, Kurt, Janzon, Magnus, Lapostolle, Frédéric, Lassen, Jens Flensted, Licour, Muriel, Merkely, Béla, Montalescot, Gilles, Silvain, Johanne, Stibbe, Olivier, Storey, Robert F., Swahn, Eva, Tsatsaris, Anne, Van't Hof, Arnoud W., Vicaut, Eric, Willems, Frank F., Zeymer, Uwe   +26 more
core   +2 more sources

Drug-like antagonists of P2Y receptors — from lead identification to drug development [PDF]

, 2016
P2Y receptors are expressed in virtually all cells and tissue types and mediate an astonishing array of biological functions, including platelet aggregation, smooth muscle cell proliferation, and immune regulation.
Conroy, Sean, Kellam, Barrie, Kindon, Nicholas, Stocks, Michael   +3 more
core   +1 more source

Navigating P2Y12 inhibition in the labyrinth of cardio-oncology care: cangrelor bridging in patients with cancer

Frontiers in Cardiovascular Medicine
Cangrelor, a potent intravenous P2Y12 platelet inhibitor, has demonstrated effectiveness in reducing ischemic events without a corresponding increase in severe bleeding during percutaneous coronary intervention, as evidenced by the CHAMPION-PHOENIX trial.
Abdelrahman Ali, Poonam Jewani, Max Bourdillon, Efstratios Koutroumpakis, Shaden Khalaf, Konstantinos Charitakis, Kara Thompson, Konstantinos Marmagkiolis, Anita Deswal, Cezar Iliescu   +9 more
doaj   +1 more source

Cangrelor [PDF]

Practical Diabetes, 2019
Arnav Katira, Ravish Katira
openaire   +1 more source

Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists [PDF]

, 2016
It has now been demonstrated that the μ, δ(1), δ(2), and κ(1) opioid receptor (OR) agonists represent the most promising group of opioids for the creation of drugs enhancing cardiac tolerance to the detrimental effects of ischemia/reperfusion (I/R ...
Bailey A, Cowan A, Dhawan BN, Emmerson PJ, Fryer RM, Fryer RM, Fryer RM, Genade S, Grekova TI, Gu H, Haddad GG, Hansen DD, Hess L, Hiranuma T, Huh J, Imai N, Kettler D, Khan MG, Kin H, Kiritsy‐Roy JA, Kisin I, Korobov NV., Krazinski BE, Kulbertus H, Lasukova TV, Lasukova TV, Lasukova TV, Lasukova TV, Lasukova TV, Lishmanov AYu, Lishmanov IuB, Lishmanov IuB, Lishmanov YuB, Liu X, Marson L, Maslov LN, Maslov LN, Maslov LN, Maslov LN, Maslov LN, Maslov LN, Maslov LN, Maslov LN, Metelitsa VI, Mikhailova SD, Monassier JP., Musha T, Panova EI., Pei JM, Platonov AA, Poonyachoti S, Pugsley MK, Pyle WG, Robson P., Saeed RW, Schultz JE, Shi E, Solenkova NV, Stefano GB, Sun HT, Ugdyzhekova DS, Varga EV, Wang GY, Wong GT, Zhang Y   +64 more
core   +2 more sources

Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib [PDF]

, 2017
The Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side-effects of ibrutinib.
Appleby, Niamh, Bruce, David, Bye, Alex P., Desborough, Michael J., Gibbins, Jon M., Hildyard, Catherine A. T., Hughes, Craig E., Kriek, Neline, Nock, Sophie H., Sage, Tanya, Unsworth, Amanda J.   +10 more
core   +2 more sources

Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing

Frontiers in Cardiovascular Medicine, 2019
Antiplatelet therapy with P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor, cangrelor) is a cornerstone of medical therapy after percutaneous coronary interventions.
Małgorzata Ostrowska, Jacek Kubica, Piotr Adamski, Aldona Kubica, Ceren Eyileten, Marek Postula, Aurel Toma, Christian Hengstenberg, Jolanta M. Siller-Matula, Jolanta M. Siller-Matula   +9 more
doaj   +1 more source

Manejo perioperatorio de fármacos anticoagulantes y antiagregantes en el paciente con fractura de cadera [PDF]

, 2016
La fractura de cadera eleva de manera significativa en los estudios publicados la morbilidad y la mortalidad en los pacientes ancianos que la padecen. La participación en el proceso de fármacos que alteran la hemostasia se ha convertido en uno de los ...
Aguar Carrascosa, Pablo, Blas Dobón, J.A., Carrera Hueso, José Adolfo, Cejalvo Andújar, María J., Martínez Gimeno, J. L., Martínez González, E., Rodrigo Pérez, José Luis   +6 more
core  

CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018 [PDF]

, 2018
While primary percutaneous coronary intervention (PCI) has significantly contributed to improve the mortality in patients with ST segment elevation myocardial infarction even in cardiogenic shock, primary PCI is a standard of care in most of Japanese ...
Akasaka, T. (Takashi), Amano, T. (Tetsuya), Hanaoka, K.I. (Keiichi Igarashi), Hikichi, Y. (Yutaka), Honye, J. (Junko), Ikari, Y. (Yuji), Inohara, T. (Taku), Kadota, K. (Kazushige), Katagiri, Y. (Yuki), Katahira, Y. (Yoshiaki), Kawai, K. (Kazuya), Kohsaka, S. (Shun), Kozuma, K. (Ken), Kyo, E. (Eisho), Matsubara, T. (Tetsuo), Michishita, I. (Ichiro), Mizuno, S. (Sumio), Muramatsu, T. (Takashi), Muramatsu, T. (Toshiya), Nakamura, M. (Masato), Nakao, K. (Koichi), Nishino, M. (Masami), Oda, H. (Hirotaka), Onuma, Y. (Yoshinobu), Otsuji, S. (Satoru), Ozaki, Y. (Yukio), Sato, K. (Katsuhiko), Sato, T. (Tadaya), Serruys, P.W.J.C. (Patrick), Shiode, N. (Nobuo), Shite, J. (Junya), Tanaka, N. (Nobuhiro), Ueda, K. (Kinzo), Uemura, M. (Mayu), Ueno, T. (Takafumi), Yokoi, H. (Hiroyoshi)   +35 more
core   +2 more sources